Costimulatory ligand CD70 allows induction of CD8+ T-cell immunity by immature dendritic cells in a vaccination setting.
about
Dendritic cell-based vaccination in cancer: therapeutic implications emerging from murine modelsTargeting the T-cell co-stimulatory CD27/CD70 pathway in cancer immunotherapy: rationale and potentialStimulating CD27 to quantitatively and qualitatively shape adaptive immunity to cancer.CD70 and IFN-1 selectively induce eomesodermin or T-bet and synergize to promote CD8+ T-cell responses.Control of established melanoma by CD27 stimulation is associated with enhanced effector function and persistence, and reduced PD-1 expression of tumor infiltrating CD8(+) T cellsCD27 sustains survival of CTLs in virus-infected nonlymphoid tissue in mice by inducing autocrine IL-2 production.Temporal changes in dendritic cell subsets, cross-priming and costimulation via CD70 control CD8(+) T cell responses to influenzaDifferential requirement for CD70 and CD80/CD86 in dendritic cell-mediated activation of tumor-tolerized CD8 T cells.Differential mechanisms of memory CD8 T cell maintenance by individual myeloid cell types.Opposing effects of CD70 costimulation during acute and chronic lymphocytic choriomeningitis virus infection of miceAn alternative signal 3: CD8⁺ T cell memory independent of IL-12 and type I IFN is dependent on CD27/OX40 signaling.Lung homing CTLs and their proliferation ability are important correlates of vaccine protection against influenzaEnhancement of dendritic cells as vaccines for cancerT cells compete by cleaving cell surface CD27 and blocking access to CD70-bearing APCs.Aging affects epidermal Langerhans cell development and function and alters their miRNA gene expression profile.The CD4⁺ T-cell help signal is transmitted from APC to CD8⁺ T-cells via CD27-CD70 interactionsCD70 is downregulated by interaction with CD27.Costimulation signals for memory CD8+ T cells during viral infections.Emerging applications of lentiviral vectors in dendritic cell-based immunotherapy.Targeting costimulatory molecules to improve antitumor immunity.The contextual role of TNFR family members in CD8(+) T-cell control of viral infections.Therapeutic targeting of CD70 and CD27.Endogenous and tumour-derived microRNAs regulate cross-presentation in dendritic cells and consequently cytotoxic T cell function.Systematic evaluation of self-adjuvanting lipopeptide nano-vaccine platforms for the induction of potent CD8(+) T-cell responses.CD70-CD27 interactions provide survival and proliferative signals that regulate T cell receptor-driven activation of human γδ peripheral blood lymphocytes.iNKT/CD1d-antitumor immunotherapy significantly increases the efficacy of therapeutic CpG/peptide-based cancer vaccine.CD27-Mediated Regulatory T Cell Depletion and Effector T Cell Costimulation Both Contribute to Antitumor Efficacy.CD70, a novel target of CAR T-cell therapy for gliomas.Compromised functionality of monocyte-derived dendritic cells in multiple myeloma patients may limit their use in cancer immunotherapy.Strategies to Genetically Modulate Dendritic Cells to Potentiate Anti-Tumor Responses in Hematologic Malignancies.
P2860
Q27012618-B9D05485-D31D-482D-A196-CFE790EBC05DQ28083873-BBA8C098-D7DF-4AE4-9A9D-D978F4D4EB63Q30252919-379BB84C-1C49-43E8-9DD4-83373D68AD18Q30278537-98C0B7C6-2AFD-459B-AA93-6227F7F83326Q30430481-97181107-79D0-4C37-8739-325ECDE4CD0AQ33559655-3CD24F84-0375-4C79-944F-A44BC55933A4Q33658250-B8745031-27D4-4AE0-BC45-7ECE35718AE6Q33768093-0750E1D3-8883-458B-AE3D-AB600BAAFF02Q33942539-3B236CA0-C90B-480E-B38D-21F35800D4F7Q35077583-FAD0060E-F4A3-48ED-8E32-AC30053BFDA6Q35717963-94C7F50F-F52D-4607-BAA2-9FC80C6F635AQ35720693-0D87DE59-617E-4A6E-A4C7-DCE94029B0BDQ36209210-08D298B2-05D6-46C6-8B06-8BE1EEB32FE2Q36359499-28F374CC-E4E7-4109-B404-0F883F836918Q36576384-7AF636C3-3736-49A7-B775-212C7BBC85F1Q36712124-FFD10D60-1609-4A09-B625-1C7080B7E916Q37112436-01518710-FAE6-4B99-A929-30BD554E312FQ37685171-EB6033B3-0F26-4179-A2D5-D2AA0859D42AQ37793233-56ED1347-1076-4204-8BB2-FF60DF8E7EFEQ38002404-F55BEE5D-7F19-47D2-AEF5-BD54D223F0DCQ38129083-A6169C95-1CD8-4FBF-9D65-D610CF2C7F8CQ38749841-205B3ECD-E38C-4BB8-9D75-74C9DB84A408Q38837651-200FCAAB-3DCC-4A6F-9B25-E9614BD3210DQ40876858-737F3F2B-DD67-4165-A342-F6A62B32292AQ42684191-CF8E0A65-F880-4444-BA7D-658DFFCBC690Q43032177-FFBD9267-93C7-4BF0-A1FD-3E709D553AC3Q47434306-CCDF99C8-5F65-415B-A141-452007ACAE23Q48223703-C27E5377-E573-48DB-AB7E-D11E6BF1BD52Q52327450-08CA2A9C-C3DF-4086-B6A2-CFA72291AB67Q55003884-B15D00B4-5C5D-4759-8AA6-51EF9F0BC775
P2860
Costimulatory ligand CD70 allows induction of CD8+ T-cell immunity by immature dendritic cells in a vaccination setting.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Costimulatory ligand CD70 allo ...... ells in a vaccination setting.
@en
Costimulatory ligand CD70 allo ...... ells in a vaccination setting.
@nl
type
label
Costimulatory ligand CD70 allo ...... ells in a vaccination setting.
@en
Costimulatory ligand CD70 allo ...... ells in a vaccination setting.
@nl
prefLabel
Costimulatory ligand CD70 allo ...... ells in a vaccination setting.
@en
Costimulatory ligand CD70 allo ...... ells in a vaccination setting.
@nl
P2093
P1433
P1476
Costimulatory ligand CD70 allo ...... ells in a vaccination setting.
@en
P2093
Anna M Keller
Jannie Borst
Shalin H Naik
Victor Peperzak
Yanling Xiao
P304
P356
10.1182/BLOOD-2008-03-148007
P407
P577
2009-03-11T00:00:00Z